Loading
A phase 3 trial testing ABBV-706 in non-small-cell lung cancer, now recruiting.
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07365241, led by AbbVie, and recruiting on the registry. Official title: A Phase 3 Randomised, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC). Planned enrolment is 531 participants (estimated). The study started in 2026-07-02 and primary completion is expected in 2030-09. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/